AFPᶜ³³²T in Advanced HCC

Hepatocellular Cancer Clinical Trial

Official title:

A Phase I Open Label Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha Fetoprotein (AFPᶜ³³²T) in HLA-A2 Positive Subjects With Advanced Hepatocellular Carcinoma (HCC) or Other AFP Expressing Tumor Types

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03132792
• Other study ID #: ADP-0033-001
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: May 8, 2017
• Est. completion date: July 7, 2036

Study information

• Verified date: August 2022
• Source: Adaptimmune
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This first time in human study is intended for men and women between 18 and 75 years of age who have advanced liver cancer which has grown or returned after being treated or another AFP expressing tumor. Those who did not tolerate or refused other therapies may also participate. The purpose of this study is to test the safety of genetically changed T cells that target alpha-fetoprotein (AFP) and find out what effects, if any, they have in subjects with liver cancer or other AFP expressing tumor types. This study is for subjects who have a blood test positive for appropriate HLA-A*02 P Group and have adequate AFP protein in blood or tumor, and whose noncancerous liver tissue has very little AFP protein (Liver only).

The study will take the subject's T cells, which are a natural type of immune cell in the blood, and send them to a laboratory to be modified. The changed T cells used in this study will be the subject's own T cells that have been genetically changed with the aim of attacking and destroying cancer cells.

The manufacturing of T cells takes about 1 month to complete. The T cells will be given back to the subject through an intravenous infusion after 3 days of chemotherapy. The study will evaluate three different cell dose levels in order to find out the target cell dose. Once the target cell dose is determined, additional subjects will be enrolled to further test the safety and effects at this cell dose.

Subjects will be hospitalized for at least 1 week after receiving their T cells back and then seen frequently by the Study Physician for the next 6 months. After that, subjects will be seen every three months. If subjects have disease progression or withdraw from the study, they will then be entered into a long-term follow up for safety monitoring. In long-term follow up, subjects will be seen every 6 months by their Study Physician for the first 5 years after the T cell infusion and annually for the next 10 years.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 45
• Est. completion date: July 7, 2036
• Est. primary completion date: July 7, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Key Inclusion Criteria:

1. Subject is = 18 years and = 75 years of age and has voluntarily agreed to participate by giving written informed consent in accordance with ICH GCP Guidelines and applicable local regulations.

2. Histologically confirmed HCC, not amenable to transplant, resection. Subjects may undergo loco-regional therapy after enrollment but not at time of lymphodepletion. Or Histologically confirmed diagnosis of another AFP expressing tumor (e.g. cholangiocarcinoma).

3. Measurable disease according to RECIST 1.1 criteria prior to lymphodepletion.

4. Progressive disease following or intolerant of or refuses standard of care systemic therapy prior to lymphodepletion.

5. Positive for any A*02:01 P group allele.

6. a) Group 1, 2, 3, (HCC) Subjects will be eligible for enrollment if they meet either one of these AFP expression criteria:

• AFP expression of =1+ in =20% of tumor cells by immunohistochemistry and their non-cancerous liver tissue has =5% cells stained for AFP at any intensity by immunohistochemistry.

• Serum AFP levels of =100ng/mL and their non-cancerous liver tissue has =5% cells stained for AFP at any intensity by immunohistochemistry.

6. b) Group 4 (other AFP expressing tumor types) Subjects will be eligible for enrollment if they meet either one of these AFP expression criteria:

o Serum AFP levels of =100ng/mL and their non-cancerous liver tissue (if applicable) has =5% cells stained for AFP at any intensity by immunohistochemistry.

7. Life expectancy of > 4 months 8. Child-Pugh score = 6 9. Eastern Cooperative Oncology Group (ECOG) 0-1 10. Subject must have adequate organ function as defined in the protocol.

Key Exclusion Criteria:

1. Positive for any of the HLA-A*02 allele other than HLA-A*02:01 P Group, HLA-A*02:03 P group or null alleles or positive for the following alleles: HLA-C*04:04 or HLA-B*51:03.

2. Prior liver transplant

3. Received the following prior to leukapheresis:

1. Cytotoxic chemotherapy, immune therapy and biological therapy within 3 weeks

2. Corticosteroids or any other immunosuppressive therapy within 2 weeks. NOTE: Use of inhaled or topical steroids is not exclusionary

3. Sorafenib/Regorafenib/Lenvatinib within 1 week

4. Cabozantinib within 2 weeks

5. Duration of treatment free intervals for any other anti-cancer therapies must be discussed with Adaptimmune Study Physician.

4. Received the following prior to lymphodepleting chemotherapy :

1. Cytotoxic chemotherapy or loco-regional therapy within 3 weeks, liver directed radiation therapy within three months.

2. Corticosteroids or any other immunosuppressive therapy within 2 weeks. NOTE: Use of inhaled or topical steroids is not exclusionary

3. Bone/soft tissue directed palliative radiotherapy within 4 weeks.

4. Investigational treatment or clinical trial within 4 weeks.

5. Sorafenib/Regorafenib/Lenvatinib within 1 week.

6. Cabozantinib within 2 weeks

7. Prior cancer-directed immunotherapy within 4 weeks, including monoclonal antibodies against PD-1 receptor or ligand.

8. Use of an experimental vaccine within 2 months in the absence of tumor response. The subject should be excluded if their disease is responding to an experimental vaccine given within 6 months

9. Any previous gene therapy using an integrated vector

10. Duration of treatment free intervals for any other anti-cancer therapies must be discussed with Adaptimmune Study Physician.

5. Toxicity persisting from previous anti-cancer therapy of = Grade 2 (except for non-clinically significant toxicities, e.g., alopecia, vitiligo). Subjects with Grade 2 toxicities that are deemed stable or irreversible (e.g. peripheral neuropathy) can be enrolled on a case-by-case basis with prior consultation and agreement with the Sponsor Study Physician.

6. Major surgery within 4 weeks prior to lymphodepletion; subjects should have been fully recovered from any surgical related toxicities.

7. Bleeding = Grade 2 in the past 3 months prior to lymphodepletion

8. Therapeutic anticoagulation from lymphodepletion until platelet count recovery (prophylactic heparin allowed)

9. Clinically or radiographically detectable ascites (beyond trace/rim of ascites) or ascites requiring medication

10. Clinically detectable hepatic encephalopathy or hepatic encephalopathy requiring medication

11. Active viral hepatitis Subjects positive for hepatitis B surface antigen not on antiviral treatment/prophylaxis or subjects with detectable hepatitis B DNA

1. Subjects with resolved (surface antigen negative, core antibody positive) or chronic stable (surface antigen positive) hepatitis B on antiviral treatment/prophylaxis with DNA levels of =100 IU/mL are allowed with HBV DNA monitoring after treatment

2. Subjects with hepatitis C allowed provided they meet all other eligibility criteria

12. Positive serology for HIV

13. Positive serology for HTLV 1 or 2

14. History of chronic or recurrent (within the last year) severe autoimmune or immune mediated disease requiring steroids or other immunosuppressive treatments. Subjects with history of idiopathic autoimmune hepatitis are excluded. Subjects who experienced hepatitis during treatment with check point inhibiting antibodies are not excluded.

15. Subject has brain metastases.

16. Other active malignancy besides HCC or other eligible AFP expressing tumor types within 3 years.

17. Electrocardiogram (ECG) showing clinically significant abnormality at Screening or showing a QTc interval =450 msec in males and =470 msec in females (=480 msec for subjects with Bundle Branch Block (BBB) over consecutive ECGs).

18. Bacterial or opportunistic infection within 3 months of treatment (upper respiratory infection and uncomplicated urinary tract infection allowed)

19. Uncontrolled intercurrent illness considered by the Investigator to add appreciable risk to study participation, including but not limited to:

1. Clinically significant cardiac disease defined by CHF New York Heart Association (NYHA) > Class 1; uncontrolled clinically significant arrhythmia in last 6 months; Acute Coronary Syndrome (ACS) (angina or myocardial infarction) in last 6 months.

2. Oxygen dependent lung disease.

3. Clinically significant psychiatric illness/social situations that would limit compliance with study requirements.

4. History of stroke or central nervous system bleeding; transient ischemic attack (TIA) or reversible ischemic neurologic deficit (RIND) in last 6 months.

20. Pregnant or breastfeeding

21. Alcohol or illicit drug dependency

22. Known contraindication to cyclophosphamide, fludarabine, mesna, G-CSF or other agents associated with study treatment.

Related Conditions & MeSH terms

• AFP Expressing Tumors
• Carcinoma, Hepatocellular
• Hepatocellular Cancer
• Liver Neoplasms

Intervention

Genetic:
• Autologous genetically modified AFP?³³²T cells
Infusion of autologous genetically modified AFP?³³²T cells

Locations

Country	Name	City	State
France	Paoli Calmettes Institute	Marseille Cedex
France	Centre Eugène Marquis	Rennes
France	Institute Gustave Roussy	Villejuif
Spain	University Hospital of Barcelona	Barcelona
Spain	University Hospital of Navarra	Pamplona
United Kingdom	Beatson West of Scotland Cancer Centre	Glasgow
United Kingdom	Guy's Hospital	London
United Kingdom	NIHR UCLH Clinical Research	London
United Kingdom	The Christie NHS Foundation Trust	Manchester
United States	Winship Cancer Institute - Emory University	Atlanta	Georgia
United States	University of Maryland, Greenebaum Cancer Center	Baltimore	Maryland
United States	Massachusetts General Hospital	Boston	Massachusetts
United States	MD Anderson Cancer Center	Houston	Texas
United States	UCLA	Los Angeles	California
United States	USC/Norris Comprehensive Cancer Center	Los Angeles	California
United States	University of Miami	Miami	Florida
United States	Mayo Clinic Arizona	Phoenix	Arizona
United States	Mayo Clinic Clinical Trial Referral Office	Rochester	Minnesota
United States	Washington University - School of Medicine	Saint Louis	Missouri
United States	Fred Hutchinson Cancer Research Centre	Seattle	Washington
United States	SCCA Immunotherapy Trials Intake	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
Adaptimmune

Countries where clinical trial is conducted

United States,  France,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of subjects with dose-limiting toxicity (DLT) and adverse events (AEs) and determination of optimally tolerated dose range, including serious adverse events (SAE).	Determine if treatment with autologous genetically modified T cells, (AFP?³³²T) is safe and tolerable through assessment of DLTs, AEs, including SAEs; laboratory assessments including chemistry, hematology, coagulation, cardiac assessments including ECG, and cardiac Troponin	2 years
Secondary	Proportion of subjects with a confirmed Complete Response (CR) or Partial Response (PR)	Evaluation of the efficacy of the treatment by assessment of the Overall Response Rate according to RECIST v1.1	2 years
Secondary	Interval between the date of first T cell infusion dose and first documented evidence of CR or PR	Evaluation of the efficacy of the treatment by assessment of time to first response	2 years
Secondary	Interval between the date of first documented evidence of CR or PR until first documented disease progression or death due to any cause	Evaluation of the efficacy of the treatment by assessment of duration of response	2 years
Secondary	Interval between the date of first documented evidence of SD until first documented disease progression or death due to any cause	Evaluation of the efficacy of the treatment by assessment of duration of stable disease	2 years
Secondary	Interval between the date of first T cell infusion and the earliest date of disease progression or death due to any cause	Evaluation of the efficacy of the treatment by assessment of progression-free survival	2 years
Secondary	Interval between the date of first T cell infusion and date of disease progression or death due to any cause	Evaluation of the efficacy of the treatment by assessment of overall survival	2 years